Coaxial MICS with toric IOL is a safe and effective treatment for cataract patients

Article

Implantation of a toric IOL after microincision cataract surgery (MICS) is a safe and successful way to correct astigmatism in cataract patients.

Implantation of a toric IOL after microincision cataract surgery (MICS) is a safe and successful way to correct astigmatism in cataract patients, stated a study published in the Journal of Cataract and Refractive Surgery.

Professor Jorge L. Alió et al., Vissum-Instituto Oftalmológico de Alicante, Spain, conducted a prospective, nonrandomized study on 21 eyes of 12 patients who had moderate to high astigmatism and cataracts. MICS was performed on all patients, followed by the implantation of an Acri.Comfort 646 TLC toric IOL in the capsular bag.

The outcome measures were uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), residual refractive sphere, residual refractive and keratometric cylinders and IOL axis alignment. All were measured 3 months postoperatively and the Alpins method was used to measure vector analysis of astigmatism.

It was found that the UDVA was 20/40 or better in 16 eyes and CDVA was 20/30 or better in 18 eyes. The mean refractive cylinder reduced postoperatively from -4.46 D ± 2.23 D to -0.45 D to 0.63 D. The mean index of success was 0.11 ± 0.15, with 91% of astigmatism corrected. Mean IOL axis rotation was -1.75˚ ± 2.93˚and the rotation was 10˚ or lower in all eyes.

The combination of MICS and toric IOL implantation posed no risks or complications. It was considered as a safe and accurate way of eradicating moderate to high astigmatism in cataract patients.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.